Cargando…
Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial
AIM: The aim of this trial (ClinicalTrials.gov identifier: NCT01280721) was to investigate the long-term safety profile of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease (ADPKD). METHODS: This open-label multicenter trial was conducted to examine adverse drug reacti...
Autores principales: | Muto, Satoru, Okada, Tadashi, Yasuda, Moriyoshi, Tsubouchi, Hidetsugu, Nakajima, Koji, Horie, Shigeo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661830/ https://www.ncbi.nlm.nih.gov/pubmed/29123425 http://dx.doi.org/10.2147/DHPS.S142825 |
Ejemplares similares
-
Effect of tolvaptan in Japanese patients with autosomal dominant polycystic kidney disease: a post hoc analysis of TEMPO 3:4 and TEMPO Extension Japan
por: Muto, Satoru, et al.
Publicado: (2021) -
Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
por: Horie, Shigeo, et al.
Publicado: (2021) -
Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]
Publicado: (2018) -
Renal disease progression in autosomal dominant polycystic kidney disease
por: Higashihara, Eiji, et al.
Publicado: (2012) -
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4
por: Devuyst, Olivier, et al.
Publicado: (2017)